Biotech · Private company · Charlottesville, VA, US
Rivus Pharmaceuticals, Inc.
SEC CIK 0001773293
Track this companyFree. Adds Rivus Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials112 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- HU6Phase 2 · Diabete Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- HU6Phase 2 · Non-Alcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- HU6Phase 2 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- HU6Phase 2 · MASH - Metabolic Dysfunction-Associated SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- HU6Phase 2 · Heart Failure With Preserved Ejection FractionClinicalTrials.gov · fetched Nov 12, 2026
- [14C]-HU6Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- HU6Phase 1 · OverweightClinicalTrials.gov · fetched Nov 12, 2026
- HU6 150 mg Capsules x 3 (Total dose = 450 mg)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- HU6 450 mg TabletPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- HU6 CapsulePhase 1 · ObeseClinicalTrials.gov · fetched Nov 12, 2026
- HU6 TabletPhase 1 · ObeseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)PHASE2 · RECRUITING · started Feb 13, 2026ClinicalTrials.gov NCT07491458 · fetched Nov 12, 2026
- Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6PHASE1 · COMPLETED · started Oct 13, 2025ClinicalTrials.gov NCT07170189 · fetched Nov 12, 2026
- Relative Bioavailability Study of HU6PHASE1 · COMPLETED · started Jul 24, 2024ClinicalTrials.gov NCT06486558 · fetched Nov 12, 2026
- A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6PHASE1 · COMPLETED · started Mar 26, 2024ClinicalTrials.gov NCT06325930 · fetched Nov 12, 2026
- Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 DiabetesPHASE2 · WITHDRAWN · started Nov 17, 2023ClinicalTrials.gov NCT06104358 · fetched Nov 12, 2026
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic SteatohepatitisPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 5, 2023ClinicalTrials.gov NCT05979779 · fetched Nov 12, 2026
- Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEFPHASE2 · COMPLETED · started Oct 30, 2022ClinicalTrials.gov NCT05284617 · fetched Nov 12, 2026
- Safety and Pharmacokinetics of HU6PHASE1 · COMPLETED · started Sep 15, 2022ClinicalTrials.gov NCT05433506 · fetched Nov 12, 2026
- Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI VolunteersPHASE2 · COMPLETED · started Apr 19, 2021ClinicalTrials.gov NCT04874233 · fetched Nov 12, 2026
- Multiple Ascending Dose Study of HU6 in High BMI VolunteersPHASE1 · COMPLETED · started Jan 4, 2021ClinicalTrials.gov NCT04709913 · fetched Nov 12, 2026
- Ascending Dose Study of HU6 in Healthy VolunteersPHASE1 · COMPLETED · started Aug 12, 2020ClinicalTrials.gov NCT04463017 · fetched Nov 12, 2026